Sign in or create an account to add this stock to your watchlist.
About Immupharma (LON:IMM)
ImmuPharma plc, a pharmaceutical company, develops drug candidates based on peptide therapeutics to treat serious medical conditions. The company's lead product candidate is the Lupuzor, which is in Phase III clinical trials for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidates include IPP-204106, an anti-cancer nucleolin antagonis peptide program that has completed Phase I/IIa clinical trials to treat cancer; IPP-102199, which is in pre-clinical development stage to treat severe pain; IPP-201007 that is in early development stage for the treatment of inflammatory and allergic conditions, such as asthma and other respiratory disorders, rheumatoid arthritis, septic shock, and acute pancreatitis; and IPP-203101, a peptide-based antibiotic, which is in pre-clinical development stage for the treatment of lethal infections, including methicillin-resistant staphylococcus aureus and other hospital acquired infections. The company's discovery pipeline includes heterocyclic ureas scaffolds; and peptide to drug converting technology that enhances a peptide's plasma half-life and efficacy. ImmuPharma plc has collaboration arrangements with the Centre National de la Recherché Scientifique; and Institut National de la Sante et de la Recherche Medicale. The company was founded in 1999 and is headquartered in London, the United Kingdom.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolLON:IMM
CUSIPN/A
Phone+44-20-71524080
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-3,507.40%
Return on Equity-101.24%
Return on Assets-86.98%
Miscellaneous
EmployeesN/A
Outstanding Shares129,670,000
Immupharma (LON:IMM) Frequently Asked Questions
What is Immupharma's stock symbol?
Immupharma trades on the London Stock Exchange (LON) under the ticker symbol "IMM."
What price target have analysts set for IMM?
4 equities research analysts have issued 12-month target prices for Immupharma's shares. Their forecasts range from GBX 181 to GBX 237. On average, they expect Immupharma's stock price to reach GBX 199.67 in the next twelve months. View Analyst Ratings for Immupharma.
Who are some of Immupharma's key competitors?
Some companies that are related to Immupharma include Mesoblast (MEOBF), Starpharma (SPL), MediGene (MDG1), Oxford BioMedica (OXB), BioTime (BTX), Resverlogix (RVX), 22nd Century Group (XXII), Protalix BioTherapeutics (PLX), Neptune Wellness Solutions (NEPT), Monash IVF Gr (MVF), Horizon Discovery (HZD), IMV (IMV), Bionomics (BNO), Fennec Pharmaceuticals (FRX) and ImmunoVaccine (IMMVF).
Who are Immupharma's key executives?
Immupharma's management team includes the folowing people:
- Mr. Dimitri F. Dimitriou M.Sc., Co-Founder, CEO & Director (Age 56)
- Dr. D. Robert Henri Zimmer M.D., Ph.D., Co-Founder, Pres, Chief Scientific Officer & Director (Age 70)
- Ms. Tracy Weimar BA, MBA, VP of Operations & Fin. and Company Sec.
- Dr. Jean-Marie Geiger PharmD, MD, Head of Clinical Devel.
- Mr. Nicholas Peter Kostopoulos, Lupuzor Director of Bus. Devel. - United States
Has Immupharma been receiving favorable news coverage?
News headlines about IMM stock have been trending somewhat positive on Thursday, according to Accern Sentiment. The research group ranks the sentiment of press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Immupharma earned a coverage optimism score of 0.02 on Accern's scale. They also gave news coverage about the company an impact score of 46.83 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
How do I buy shares of Immupharma?
Shares of IMM and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Immupharma's stock price today?
One share of IMM stock can currently be purchased for approximately GBX 28.70.
How big of a company is Immupharma?
Immupharma has a market capitalization of £174.33 million.
How can I contact Immupharma?
Immupharma's mailing address is 50 Broadway, LONDON, SW1H 0BL, United Kingdom. The company can be reached via phone at +44-20-71524080.
MarketBeat Community Rating for Immupharma (IMM)
MarketBeat's community ratings are surveys of what our community members think about Immupharma and other stocks. Vote "Outperform" if you believe IMM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMM will underperform the S&P 500 over the long term. You may vote once every thirty days.
Immupharma (LON:IMM) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for Immupharma in the last 12 months. Their average twelve-month price target is GBX 199.67The high price target for IMM is GBX 237 and the low price target for IMM is GBX 181. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | GBX 199.67 | GBX 199.67 | GBX 174.75 | GBX 154 |
Immupharma (LON:IMM) Consensus Price Target History
Immupharma (LON:IMM) Analyst Ratings History
Show:
(Data available from 5/24/2016 forward)
Immupharma (LON:IMM) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Immupharma (LON IMM) Insider Trading and Institutional Ownership History
Immupharma (LON IMM) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
(Data available from 1/1/2013 forward)
Immupharma (LON IMM) News Headlines
| Source: |
|
Immupharma (LON:IMM) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Immupharma (LON IMM) Stock Chart for Thursday, May, 24, 2018
Loading chart…
